Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis

Inclusion Criteria: * Adult men and women aged 19 to 75 years at the time of written informed consent * Diagnosed with EE on an upper gastrointestinal endoscopy prior to the initiation of standard therapy * Healing of EE confirmed by upper gastrointestinal endoscopy performed prior to Visit 2 (Randomization), defined as the absence of mucosal breaks according to the LA Grade classification, after completion of standard therapy * Able to understand the information provided and complete the questionnaire * Has voluntarily decided to participate in this clinical trial and has provided written informed consent Exclusion Criteria: * Presence of heartburn or acid regurgitation within 7 days prior to Visit 2 (Randomization) * On screening upper gastrointestinal endoscopy, presence of Barrett's esophagus (\>3 cm), esophageal varices, esophageal stricture, ulcer-related stricture, active peptic ulcer, acute gastrointestinal bleeding, or malignancy * Patients with inflammatory bowel disease , irritable bowel syndrome, primary esophageal motility disorder, or pancreatitis * History of gastric acid secretion-inhibiting surgery or surgery on the stomach/esophagus (e.g., gastrectomy, endoscopic mucosal resection) or total small bowel resection * Presence of alarm symptoms suggestive of gastrointestinal malignancy * Patients with Zollinger-Ellison syndrome * Patients with eosinophilic esophagitis * Subjects with diseases of the liver, kidney, nervous system, respiratory system, endocrine…